Langley Paul C
a College of Pharmacy, University of Minnesota, MN, USA, and Maimon Research LLC , Tucson , AZ , USA.
J Med Econ. 2015;18(12):991-2. doi: 10.3111/13696998.2015.1108920. Epub 2015 Nov 7.
The only acceptable modeled claims for costs and outcomes are those that are testable and can be validated in a timeframe that is acceptable to a formulary committee. This issue provides four papers which explore the methodological issues in validation, the UK experience with NICE, the questions a formulary committee should ask of modeled claims, and the role of Big Data in validating modeled claims.
